All In Biotech

Drug Trial Radar · NCT01109693

Strategic Use of New Generation Antidepressants for Depression

Last checked: Nov 20, 2026Latest source record: Oct 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,011 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,011

Actual

Start

Dec 2010

Primary completion

Sep 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Kyoto UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Center of Neurology and Psychiatry, Japan
First posted
Apr 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to establish the optimum treatment strategy for first-line and second-line antidepressants in the acute phase treatment of major depression.

Conditions

  • Unipolar Major Depressive Episode

Interventions

  • SertralineDrug

    Sertraline 50 mg/d or 100 mg/d for 6 more weeks

  • MirtazapineDrug

    Augment with or switch to mirtazapine 15-45 mg/d

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observer-rated depression severity (PHQ-9)Time frame: 9 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • Kochi Medical School Hospital

    Nangoku, Kochi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.